Parkinson's Program

About Araclon Biotech

Araclon Biotech, founded in 2004 and based in Zaragoza, Spain, is a Grifols subsidiary dedicated to tackling Alzheimer's Disease through early diagnostics and active immunotherapy. Its core technology platform centers on measuring amyloid-beta peptides (Aβ40 and Aβ42) in blood plasma, providing a less invasive alternative to cerebrospinal fluid or PET imaging for early detection. The company's lead therapeutic candidate, ABvac40, is an active vaccine targeting the Aβ40 peptide, and it has begun preclinical research into Parkinson's disease through a collaboration with the Spanish National Research Council (CSIC). As a fully integrated R&D unit within Grifols, Araclon leverages its parent company's resources while pursuing a high-risk, high-reward strategy in the neurodegenerative disease space.

About ProMIS Neurosciences

ProMIS Neurosciences is a clinical-stage biotech leveraging its proprietary EpiSelect™ computational platform to design selective antibodies against toxic misfolded proteins in neurodegenerative diseases. Its lead program, PMN310 for Alzheimer's disease, is in a Phase 1b trial and has received FDA Fast Track designation, with a strategic goal of advancing directly to a registrational study. The company, headquartered in Toronto and Cambridge, is publicly traded on Nasdaq (PMN) and secured a significant financing package in early 2026, extending its cash runway through 2027.

Therapeutic Areas

Other Parkinson's Disease Drugs